RNS

Released : February 13, 2018 07:00   RNS Number : 6464E MaxCyte, Inc. 13 February 2018       MaxCyte, Inc. ("MaxCyte" or the "Company")   Dr Richard Douglas Joins MaxCyte Board   Dr Douglas previously served as Senior Vice President of Corporate Development at Genzyme   Gaithersburg, Maryland - 13
Feb 13, 2018
Released : February 01, 2018 16:06   RNS Number : 6932D MaxCyte, Inc. 01 February 2018   SCHEDULE 6 AIM BLOCK ADMISSION SIX MONTHLY RETURN   Please ensure the entries on this return are typed   a. Name of company   MaxCyte, Inc.   b. Name of scheme(s)   MaxCyte Long Term Incentive Plan   c.
Feb 02, 2018
Released : January 23, 2018 13:32   RNS Number : 6888C MaxCyte, Inc. 23 January 2018         MaxCyte, Inc. ("MaxCyte" or the "Company")   Total Voting Rights   Maryland, USA - 23 January 2018:  MaxCyte (LSE: MXCT, MXCR)  announces that, following an exercise of options, 18,293 new shares of common
Jan 23, 2018
Released : January 22, 2018 07:00   RNS Number : 4641C MaxCyte, Inc. 22 January 2018       MaxCyte, Inc. ("MaxCyte" or the "Company")   Trading Update   Gaithersburg, Maryland - 22 January 2018: MaxCyte (LSE: MXCT, MXCR), a US-based global company driving the acceleration of the discovery,
Jan 22, 2018
Released : January 12, 2018 17:13   RNS Number : 7976B MaxCyte, Inc. 12 January 2018         MaxCyte, Inc. ("MaxCyte" or the "Company")   Total Voting Rights   Maryland, USA - 12 January 2018:  MaxCyte (LSE: MXCT, MXCR)  announces that, following an exercise of options, 18,293 new shares of common
Jan 12, 2018
Released : November 30, 2017 15:26   RNS Number : 0291Y MaxCyte, Inc. 30 November 2017         MaxCyte, Inc. ("MaxCyte" or the "Company")   Total Voting Rights   Maryland, USA - 30 November 2017: MaxCyte (LSE: MXCT, MXCR) announces that, following an exercise of options, 41,121 new shares of common
Nov 30, 2017
Released : October 31, 2017 12:47   RNS Number : 1243V MaxCyte, Inc. 31 October 2017         MaxCyte, Inc. ("MaxCyte" or the "Company")   Result of AGM   Maryland, USA - 31 October 2017:   MaxCyte (LSE: MXCT, MXCR), a US-based global company driving the acceleration of the discovery, development,
Oct 31, 2017
Released : October 16, 2017 07:00   RNS Number : 6267T MaxCyte, Inc. 16 October 2017         MaxCyte, Inc. ("MaxCyte" or the "Company")   Declaration of Audit Remuneration   Maryland, USA - 16 October 2017:   MaxCyte (LSE: MXCT, MXCR), in order to assist investors in considering the resolutions
Oct 16, 2017
Released : October 05, 2017 18:32   RNS Number : 8773S MaxCyte, Inc. 05 October 2017   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
Oct 05, 2017
Released : October 05, 2017 18:31   RNS Number : 8770S MaxCyte, Inc. 05 October 2017   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
Oct 05, 2017